The effect of exogenous testosterone on total and free prostate specific antigen levels in healthy young men

Journal of Urology

Volumn 156, Issue 2, 1996, Pages 438-442

  Cooper, Christopher S ^a   Macindoe, John H ^a   Perry, Paul J ^a   Yates, William R ^a   Williams, Richard D ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Androgens; Prostate; Prostate specific antigen; Sex hormones; Testosterone

Indexed keywords

EID: 1842584526     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)65871-3     Document Type: Article

References (35)

1. Watt, K. W., Lee, P. J., M'Timkulu, T., Chan, W. P. and Loor, R.: Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc. Natl. Acad. Sci., 83: 3166, 1986.
2. Culig, Z., Hobisch, A., Cronauer, M. V., Radmayr, C., Trapman, J., Hittmair, A., Bartsch, G. and Klocker, H.: Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res., 54: 5474, 1994.
3. Young, C. Y., Montgomery, B. T., Andrews, P. E., Qiu, S. D., Bilhartz, D. L. and Tindall, D. J.: Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res., 51: 3748, 1991.
4. Henttu, P., Liao, S. S. and Vihko, P.: Androgens up-regulate the human prostate-specific antigen messenger ribonucleic acid (mRNA), but down-regulate the prostatic acid phosphatase mRNA in the LNCaP cell line. Endocrinology, 130: 766, 1992.
5. Israeli, R. S., Powell, C. T., Corr, J. G., Fair, W. R. and Heston, W. D.: Expression of the prostate-specific membrane antigen. Cancer Res., 54: 1807, 1994.
6. Bilhartz, D. L., Tindall, D. J. and Oesterling, J. E.: Prostate-specific antigen and prostatic acid phosphatase: biomolecular and physiologic characteristics. Urology, 38: 95, 1991.
7. Gleave, M. E., Hsieh, J. T., Wu, H. C., von Eschenbach, A. C. and Chung, L. W.: Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res., 52: 1598, 1992.
8. Kaufman, M., Pinsky, L., Trifiro, M., Lumbroso, R., Sabbaghian, N. and Gottlieb, B.: Kinetic evidence for a unique testosterone-receptor complex in 5 alpha-reductase sufficient genital skin fibroblasts and the effects of 5 alpha-reductase deficiency on its formation. J. Steroid Biochem. Molec. Biol., 45: 467, 1993.
9. Kokontis, J., Takakura, K., Hay, N. and Liao, S.: Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res., 54: 1566, 1994.
10. Murtha, P., Tindall, D. J. and Young, C. Y.: Androgen induction of a human prostate-specific kallikrein, hKLK2: characterization of an androgen response element in the 5′ promoter region of the gene. Biochemistry, 32: 6459, 1993.
11. Riegman, P. H., Vlietstra, R. J., van der Korput, J. A., Romijn, J. C. and Trapman, J.: Characterization of the prostate-specific antigen gene: a novel human kallikrein-like gene. Biochem. Biophys. Res. Comm., 159: 95, 1989.
12. Geller, J.: Basis for hormonal management of advanced prostate cancer. Cancer, suppl., 71: 1039, 1993.
13. Siiteri, P. K. and Simberg, N. H.: Changing concepts of active androgens in blood. Clin. Endocr. Metab., 15: 247, 1986.
14. Akakura, K., Bruchovsky, N., Goldenberg, S. L., Rennie, P. S., Buckley, A. R. and Sullivan, L. D.: Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer, 71: 2782, 1993.
15. Bruchovsky, N., Goldenberg, S. L., Akakura, K. and Rennie, P. S.: Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol. Cancer, 72: 1685, 1993.
16. Gonzalez-Barcena, D., Vadillo-Buenfil, M., Gomez-Orta, F., Fuentes Garcia, M., Cardenas-Cornejo, I., Graef-Sanchez, A., Comaru-Schally, A. M. and Schally, A. V.: Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer. Prostate, 24: 84, 1994.
17. Beisland, H. O., Binkowitz, B., Brekkan, E., Ekman, P., Kontturi, M., Lehtonen, T., Lundmo, P., Pappas, F., Round, E., Shapiro, D., Stoner, E., Swartz, R. and Varenhorst, E.: Scandinavian clinical study of finasteride in the treatment of benign prostatic hyperplasia. Eur. Urol., 22: 271, 1992.
18. Behre, H. M. and Nieschlag, E.: Testosterone buciclate (20 Aet-1) in hypogonadal men: pharmacokinetics and pharmacodynamics of the new long-acting androgen ester. J. Clin. Endocr. Metab., 75: 1204, 1992.
19. Behre, H. M., Bohmeyer, J. and Nieschlag, E.: Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin. Endocr., 40: 341, 1994.
20. Tenover, J. S.: Effects of testosterone supplementation in the aging male. J. Clin. Endocr. Metab., 75: 1092, 1992.
21. Wallace, E. M., Pye, S. D., Wild, S. R. and Wu, F. C.: Prostate-specific antigen and prostate gland size in men receiving exogenous testosterone for male contraception. Int. J. Androl., 16: 35, 1993.
22. Holmäng, S., Mårin, P., Lindstedt, G. and Hedelin, H.: Effect of long-term oral testosterone undecanoate treatment on prostate volume and serum prostate-specific antigen concentration in eugonadal middle-aged men. Prostate, 23: 99, 1993.
23. Horton, R., Pasupuletti, V. and Antonipillai, I.: Androgen induction of steroid 5 alpha-reductase may be mediated via insulin-like growth factor-I. Endocrinology, 133: 447, 1993.
24. Weber, J. P., Oesterling, J. E., Peters, C. A., Partin, A. W., Chan, D. W. and Walsh, P. C.: The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostatic hyperplasia. J. Urol., 141: 987, 1989.
25. Stamey, T. A., Kabalin, J. N., McNeal, J. E., Johnstone, I. M., Freiha, F., Redwine, E. A. and Yang, N.: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J. Urol., 141: 1076, 1989.
26. Horton, R.: Benign prostatic hyperplasia: new insights. J. Clin. Endocr. Metab., 74: 504A, 1992.
27. George, F. W., Russell, D. W. and Wilson, J. D.: Feed-forward control of prostate growth: dihydrotestosterone induces expression of its own biosynthetic enzyme, steroid 5 alpha-reductase. Proc. Natl. Acad. Sci., 88: 8044, 1991.
28. Beckmann, M. W., Wieacker, P., Dereser, M. M., Flecken, U. and Breckwoldt, M.: Influence of steroid hormones on 5 alpha-reductase activity in female and male genital skin fibroblasts in culture. Acta Endocr., 128: 161, 1993.
29. Pierrepoint, C. G., Davies, P., Millington, D. and John, B.: Evidence that the differential vein acts as a local transport system for androgen in the rat and the dog. J. Reprod. Fertil., 43: 293, 1975.
30. Griffiths, K., Eaton, C. L., Harper, M. E., Peeling, B. and Davies, P.: Steroid hormones and the pathogenesis of benign prostatic hyperplasia. Eur. Urol., suppl., 20: 68, 1991.
31. Fjösne, H. E., Haug, E. and Sunde, A.: Androgen metabolism in the different lobes of the prostate gland of intact, gonadectomized or hypophysectomized rats with or without androgen substitution. Scand. J. Clin. Lab. Invest., 54: 83, 1994.
32. Shao, T. C., Kong, A., Marafelia, P. and Cunningham, G. R.: Effects of finasteride on the rat ventral prostate. J. Androl., 14: 79, 1993.
33. Shao, T. C., Kong, A. and Cunningham, G. R.: Effects of 4-MAPC, a 5 alpha-reductase inhibitor, and cyproterone acetate on regrowth of the rat ventral prostate. Prostate, 24: 212, 1994.
34. Fong, C.-J., Sutkowski, D. M., Braun, E. J., Bauer, K. D., Sherwood, E. R., Lee, C. and Kozlowksi, J. M.: Effect of retinoic acid on the proliferation and secretory activity of androgen-responsive prostatic carcinoma cells. J. Urol., 149: 1190, 1993.
35. Ruizeveld de Winter, J. A., Janssen, P. J., Sleddens, H. M., Verleun-Mooijman, M. C., Trapman, J., Brinkmann, A. O., Santerse, A. B., Schröder, F. H. and van der Kwast, T. H.: Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Amer. J. Path., 144: 735, 1994.